injectable drug 2 . XDR-TB has incredibly poor treatment outcomes: in one long-term cohort of patients with XDR-TB in South Africa, only 19% of patients had a favorable outcome 4 .
The global frontline molecular diagnostic for drug-resistant M. tuberculosis, Xpert MTB/RIF, simultaneously detects the presence of M. tuberculosis and identifies rifampicin resistance 5 . Although this assay identifies patients harboring rifampicin-resistant strains for the initiation of MDR-TB treatment, it may not identify resistance at the earliest available opportunity. In a recent analysis of genomes from a large collection of M. tuberculosis clinical isolates from South Africa 6 , Cohen et al. showed that the overwhelming majority of MDR-TB and XDR-TB strains evolved resistance to isoniazid before resistance to rifampicin. This result was consistent with another recent genomic analysis of strains from Russia 7 and from an MDR-TB outbreak in Argentina 7 . In addition, analysis of phenotypic drug-susceptibility tests from a large, global collection of strains collected during TB drug resistance surveys indicated that isoniazid resistance is acquired before rifampicin resistance 8 . Furthermore, a recent meta-analysis revealed that patients harboring isoniazid-resistant strains have higher rates of treatment failure, relapse and acquisition of multidrug resistance relative to patients with drug-susceptible strains 9 .
Collectively, these results suggest that, to detect resistance as soon as possible and to prevent MDR-TB and XDR-TB strains from evolving, molecular diagnostic tests for M. tuberculosis should include the earliest resistance-conferring mutations to emerge; however, the identities of these MDR 'harbinger' mutations remain undefined. To close this gap in understanding, we undertook a large-scale analysis of a global data set of whole-genome sequences from 5,310 M. tuberculosis strains, including 868 newly sequenced strains and 4,442 previously published strains, to determine the order of acquisition of drugresistance mutations and to identify which mutations occur early along the pathway toward MDR and which might, therefore, serve as early sentinels in the development of MDR.
RESULTS

Drug resistance arises by similar mechanisms across the globe
To examine global phylogeographical patterns, including the order of evolution of drug-resistance mutations in M. tuberculosis, we compiled a set of 8,316 whole-genome sequences from clinical M. tuberculosis strains that were either newly sequenced as part of this study or were sequenced as part of 14 published studies that used Illumina technology ( Supplementary Table 1 ) 6, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . After quality filtering (Online Methods), our data set included 5,310 genome sequences that represented M. tuberculosis strains from 48 countries and 17 United Nations (UN)-defined geographical regions (Supplementary Figs. 1-4,  Supplementary Tables 1-3 and Supplementary Note). Although our data set represented a broad diversity of TB strains from many global regions, the phylogeographical distribution of the strains did not perfectly match the actual distribution of TB burden worldwide ( Supplementary Fig. 1b) ; however, all seven known global lineages of M. tuberculosis 24 were represented (lineage 1, EAI or Indo-Oceanic lineage; lineage 2, Beijing lineage; lineage 3, CAS or Central Asian lineage; lineage 4, Euro-American lineage; lineage 5, Mycobacterium africanum West African type I; lineage 6, M. africanum West African type II; and the deep-branching lineage 7), as well as Mycobacterium bovis. As expected, lineages 1-4 were predominant (99.2%), consistent with the previously described limited geographical and host distributions of lineages 5-7 ( Supplementary Table 3 ) 22, 25, 26 .
To examine the distribution of drug resistance in our sample, for each of the isolate genomes, we computationally predicted resistance to eight drugs 27 using a curated list of polymorphisms associated with resistance ( Supplementary Table 4 ). Because phenotypic drug-resistance information was unavailable for most of the data sets, we did not incorporate phenotypic information into our analysis. We identified a total of 392 unique drug-resistance-associated polymorphisms in at least one strain ( Supplementary Tables 2 and 5 Table 6 ).
Another 409 (8%) strains carried mutations causing pre-XDR levels of resistance (MDR genotype plus mutations conferring resistance to either ofloxacin or kanamycin). Over half of the sequenced strains did not have any resistance-conferring mutation and were thus predicted to be drug susceptible ( Fig. 1, Supplementary Figs. 4-6 and Supplementary Table 2 ). Drug resistance was identified in nearly all (15 of 17) of the UN regions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) for which we had data, although its regional distribution varied considerably (Supplementary Figs. 7-10 and Supplementary Note). In certain regions of the globe, we observed large numbers of closely related strains with nearly identical sets of resistance-conferring mutations, which could be attributed to clonal transmission. Because our data set contained isolates from several known outbreaks 6, 13 , rather than focusing on the total number of strains with each mutation, we instead examined the number of times each mutation evolved in different global regions by counting independent arisals, or the number of separate evolutions of a specific mutation occurring at defined positions in the phylogeny for a specific geography. Using parsimony-based analysis to reconstruct mutation gains and losses at all nodes across the phylogeny (Online Methods), we observed that the distribution of arisals of specific mutations was fairly constant across the globe, in contrast to the uneven distribution of strains with these mutations ( Supplementary Tables 7 and 8 , and Supplementary Note), suggesting that drug resistance has arisen via similar mechanisms irrespective of geography. This was also true for the evolution of MDR and XDR strains, which we calculated within our data set to have evolved independently 573 and 138 times, respectively. Along with frequent, repeated, de novo arisals, person-to-person transmission-as predicted when all strains descending from a common ancestor in the phylogeny shared the same MDR genotype-was also an important contributor to the observed MDR cases. Of the 573 arisals, 360 (63%) led to a single MDR strain in our data set (de novo evolution), whereas 213 arisals (37%) resulted in two or more descendant MDR strains, probably indicating person-to-person transmission of MDR-TB.
Isoniazid resistance overwhelmingly arises before rifampicin resistance across all lineages, geographical regions and time
In an earlier analysis involving a smaller data set of strains from South Africa 6 , we showed that isoniazid resistance evolved before rifampicin resistance in almost all cases. To determine whether this ordering of mutation acquisition was also observed in a globally diverse set of strains, we used a parsimony-based analysis to examine the order of pairwise arisals of drug-resistance mutations. We filtered out portions of the phylogeny with ambiguous topologies (Online Methods) and only included nodes at which explicit ordering could be established 6 . In agreement with our previous results 6 , we found that resistance to first-line drugs generally evolved before resistance to second-line drugs (Supplementary Note), as would be expected from the order INH1 STR INH2 RIF EMB ETH PZA OFL KAN  -19  12  114  82  28  30  63  62  4  -16  110 103  48  39  92  67  0  1  -41  27  9  14  72  57  2  7  5  -43  28  32  88  75  1  2  4  38  -13  23  91  61  0  0  2  16  10  -11  34  18  0  0  0  3  1  1  -27  33  0  1  0  1  0  1  1  -19  0  1  2  3 Figure 2 Across the globe, isoniazid resistance was overwhelmingly the first step toward drug resistance. Acquisition of a katG mutation affecting Ser315 preceded that of all other drug-resistance-conferring mutations for the majority of instances in which the order of acquisition could be disambiguated. We quantified the pairwise number of evolutions in which resistance to one drug preceded resistance to a second drug. Reported numbers represent the number of independent evolution events (not the number of strains) in which resistance to the drug indicated in the row labeled "first resistance" was acquired before resistance to the drug indicated in the column labeled "second resistance." Shading color indicates the percentage of evolutionary events in which resistance to the first drug clearly predates resistance to the second drug in that drug pair. Although mutations in inhA can confer resistance to both isoniazid and ethionamide 64 , we defined genotypic ethionamide resistance as being conferred by mutations in only ethA to simplify the analysis and to avoid double counting. Figure 3 Sequential acquisition of drug-resistance-conferring mutations shows that isoniazid-resistance-conferring mutations, specifically katG mutation encoding p.Ser315Thr, most often come first in sequential pairs of mutations. This figure includes data from 71 drug-resistance-conferring mutations with at least ten occurrences in our data set, which represent 93% of all drug-resistance-conferring mutations in our data set. We used PAUP analysis to assign gains of specific mutations to individual nodes on the phylogeny and tabulated all routes of drug-resistance acquisition across the full strain phylogeny, examining only nodes on the tree where drug-resistance mutations arose (i.e., node 1 (mutation A) → node 2 (mutations B and C) → node 3 (mutation D)). We tabulated the number of times each pair of mutations arose sequentially at adjacent nodes (i.e., mutations A → B, A → C, B → D, and C → D). We removed node pairs that did not meet specific bootstrap and branch-length criteria (Online Methods). The ribbons in this figure depict the number of times that each pair of mutations arose sequentially at adjacent nodes across the entire data set. The width of the ribbon at each end is proportional to the number of times mutation A arose before mutation B, or vice versa (i.e., a ribbon with a thick end at katG p.Ser315Thr and a thin end at rpoB p.Ser450Leu indicates that katG p.Ser315Thr arose before rpoB p.Ser450Leu much more frequently than the reverse). Each ribbon is colored according to the mutation that more often occurred first in each sequential pairing.
in which antituberculosis drugs are used in clinical practice. We also observed that mutations conferring isoniazid resistance overwhelmingly arose before any other mutation implicated in resistance ( Fig. 2 , Supplementary Table 9 and Supplementary Note), despite substantial complexity in the types and ordering of the mutations within our data set ( Fig. 3) . Notably, isoniazid resistance predated rifampicin resistance in 96% of pairwise comparisons (155 of 162), a pattern that remained true regardless of lineage or geographical source ( Fig. 4) . Although the majority of this effect was due to mutations in the katG gene encoding catalase-peroxidase (98%; 114 of 116 pairings), non-katG-associated mutations for isoniazid resistance followed this same pattern (89%; 41 of 46 pairings). Thus, the provenance of global MDR was overwhelmingly isoniazid-resistant strains. In particular, strains carrying a katG mutation encoding a p.Ser315Thr substitution frequently gained rifampicin resistance, whereas only a very small minority (4%) of global MDR arisals were due to a gain of isoniazid resistance on a rifampicin-resistant background, despite the presence of 48 rifampicin-monoresistant strains and of 152 (3% of total) isolates that were rifampicin resistant but not resistant to isoniazid.
One possible explanation for this notable result is that isoniazid entered into clinical use approximately 20 years before rifampicin (rifampicin was introduced between 1971 and 1993, depending on geography) 28 , resulting in ancestral M. tuberculosis populations that had different amounts of exposure to these drugs, which could have affected the order of acquisition of drug resistance to favor resistance to isoniazid before rifampicin resistance. To test this hypothesis, we predicted the date for the arisal of each isoniazid-or rifampicinresistance mutation using the BEAST software 29 and then tallied the number of co-arisals of resistance to both drugs that occurred during various time periods, starting from a fixed date in the past and extending to the present, (Online Methods), starting at 1971 (the date of introduction of rifampicin) and ending at 2000 (a later date included to account for the lag in timing for the widespread use of rifampicin) ( Supplementary Tables 9-11 ). Our results showed that, regardless of the time period or evolutionary rate chosen (Online Methods and Supplementary Note), resistance mediated by katG mutation affecting Ser315 arose before rifampicin resistance 92-98% of the time ( Supplementary Table 10 ), indicating that, even during the era when isoniazid and rifampicin were given in combination, the emergence of isoniazid resistance predated that of rifampicin resistance.
Diagnostics for early detection of pre-MDR M. tuberculosis
Contributors to the current global burden of MDR-TB include not only historical emergences of MDR strains, which led to person-to-person transmission of MDR-TB, but also ongoing de novo evolution. Of the 573 MDR arisals in our data set, we estimated that 67% occurred since 2004. Thus, new strategies for curbing the emergence of MDR strains, such as identifying strains that are precursors to MDR strains, will be critical to the control of MDR strains worldwide. Xpert MTB/RIF, currently one of the frontline diagnostic tests used to exclusively identify rifampicin-resistance-conferring mutations in the rifampicinresistance-determining region (RRDR) of rpoB 5 , is commonly used globally as a proxy for detecting MDR-TB. The most common ordering observed, of isoniazid resistance before rifampicin resistance, indicates that Xpert MTB/RIF serves as an appropriate proxy for MDR-TB and is well-suited to detect MDR strains in all geographical regions and all lineages of M. tuberculosis (Fig. 4) . However, because mutations that result in rifampicin resistance (detectable by Xpert MTB/RIF) are rarely the first drug-resistance-conferring mutations to emerge, oftentimes by the time a mutation that is detectable by the Xpert MTB/RIF assay develops, there is pre-existing resistance to multiple additional drugs, including second-line drugs (Fig. 5) . Because we excluded nodes at which we were unable to disambiguate the relative ordering of the acquisition of pairs of drug-resistance-associated mutations, our estimates represent a lower bound on the number of nodes at which resistance to other drugs was gained before a rifampicin-resistance-conferring mutation could be detected by the Xpert MTB/RIF ( Supplementary Fig. 11 ).
Diagnostics that identify mutations present before the emergence of multidrug resistance would provide an opportunity to identify drug resistance during a period in which there are both greater therapeutic options and improved treatment outcomes 30 . Although the results from our pairwise ordering of resistance acquisition clearly demonstrated that katG p.Ser315Thr-mediated isoniazid resistance is among the earliest to evolve, our pairwise approach necessarily oversimplified the complex process of MDR-TB evolution. Thus, in a complementary approach to identify other possible sentinels of complex resistance, we cataloged all of the resistance-conferring mutations that commonly evolved before the development of MDR-TB (which we refer to as 'pre-MDR-TB mutations'). For this set of mutations, we quantified the fraction of MDR-defining nodes at which one of these pre-MDR-TB mutations had evolved before the development of MDR-TB to determine how much resistance to other drugs had unambiguously arisen before the emergence of multidrug resistance (Fig. 6) . Our analysis identified a set of 16 resistance-conferring mutations (of 340 total found among MDR and XDR strains) that arose before MDR-TB a minimum of two independent times ( Supplementary Table 12 and Supplementary Note).
Unexpectedly, we observed resistance-conferring mutations for all eight drugs among this set of pre-MDR-TB mutations. However, many of these mutations evolved infrequently (Fig. 6b) , and thus would likely have low negative predictive value if their sequences were included on a diagnostic panel aimed at identifying pre-MDR-TB. In contrast, the katG mutation encoding p.Ser315Thr, which confers isoniazid resistance, stood out as a frequently occurring mutation ( Fig. 6b) with very few instances of resistance to other drugs arising before its gain (Fig. 6a) . Despite the high level of complexity in the stepwise acquisition of drug-resistance-conferring mutations in M. tuberculosis (Fig. 3) , the katG mutation encoding p.Ser315Thr was by far the most common mutation to evolve before the emergence of multidrug resistance (Fig. 2, Supplementary Tables 12 and 13 , and Supplementary Note). Of the 321 independent arisals of katG p.Ser315Thr in our data set, 302 (94%) occurred at the earliest node in which drug resistance was present.
DISCUSSION
We constructed the largest global data set of M. tuberculosis whole genomes analyzed to date, consisting of genomes from 5,310 diverse strains. Although the global distribution of strains in this data set does not reflect the global incidence of TB for some regions (Supplementary Fig. 1b) , our unique data set had a broad geographical distribution and deep sampling of drug-resistant strains, including MDR and XDR strains from multiple lineages and regions. We were, therefore, able to dissect the step-by-step evolution of drug resistance and to identify harbinger resistance-conferring mutations that emerged before development of MDR-TB.
We observed that MDR-TB and XDR-TB evolved many independent times, in different lineages and regions of the world, suggesting that there are many 'permissive' environments that have allowed MDR-TB and XDR-TB to emerge repeatedly. Molecular diagnostic tests for drug-resistant TB could be improved by incorporating knowledge of the global patterns of resistance emergence. We observed that the distribution of arisals of specific resistance-conferring mutations was fairly constant across the globe, indicating that drug resistance has arisen via common mechanisms worldwide. Thus, a universal diagnostic for detecting resistance to the eight drugs examined here may be achievable without the need for regional specialization. Without phenotypic drug-susceptibility data for all included strains, we were not able to identify previously unknown drug-resistance-conferring mutations or to quantify the amount of drug resistance that remains unexplained by our curated list of polymorphisms; however, we expect this amount to be small 27 .
By dissecting the step-by-step evolution of drug-resistant M. tuberculosis across the phylogeny, we observed that patterns in the order of emergence of drug resistance also appeared to be conserved globally. In particular, across all lineages and geographical regions, isoniazid resistance overwhelmingly arose before rifampicin resistance. Some regions of the world, such as Iran 31 , are reported to have a high incidence of rifampicin resistance; however, our results suggest that rifampicin monoresistance rarely leads to MDR-TB. Although the effects of convergent evolution among frequently evolving mutations could cause isoniazid resistance evolutions to be dated further back in time than when they actually occurred, we took care to minimize such effects (Supplementary Note). In support of our results, this relative ordering of isoniazid and rifampicin resistance is consistent with prior findings based on genomic data showing that isoniazid resistance arises before rifampicin resistance in Russia 7 , South Africa 6 and South America 7 , as well as with analysis of a large global collection of phenotypic data 8 .
Why would isoniazid resistance arise first? We showed that the earlier clinical introduction of isoniazid was not a major contributor to the earlier arisal of isoniazid resistance; our dating analysis indicates that isoniazid resistance arose before rifampicin resistance across all time periods, including recently (Supplementary Note). However, there are many alternative, although not definitive, explanations for this preferential ordering. Isoniazid is a prodrug, which must first be Figure 6 katG p.Ser315Thr is a commonly occurring mutation with very little resistance to other drugs arising prior to its occurrence. (a) The percentage of nodes at which resistance to another drug unambiguously preceded the arisal of the indicated mutation, for each of the 16 pre-MDR mutations. The percentage of nodes at which another drug-resistanceconferring mutation had already arisen prior to the pre-MDR mutation is likely much higher, as we were unable to disambiguate ordering for a substantial number of nodes for which additional mutations arose at the same node. (b) The number of independent arisals for each of the 16 pre-MDR (or harbinger) mutations. Because there are two mutations at the Met306 codon in embB, the nucleotide change at position 4,247,609 is also indicated for these two variants.
A r t i c l e s activated by KatG (encoded by katG), the catalase-peroxidase 32 , to form an adduct with nicotinamide adenine dinucleotide (NAD) 33 , which then inhibits InhA (encoded by inhA), an NADH-dependent enoyl-acyl carrier protein reductase 34 , and ultimately inhibits mycolic acid biosynthesis 35 . The major mechanisms of isoniazid resistance include mutations in katG, a non-essential gene, which result in failure to activate isoniazid, and either upregulation or target modification of InhA. Rifampicin inhibits the β subunit of the mycobacterial RNA polymerase, encoded by a single, essential gene, rpoB 36 . M. tuberculosis cells grown in vitro have higher spontaneous mutation rates toward isoniazid resistance than rifampicin resistance 37, 38 , which could be due to the greater number of mutations that can lead to isoniazid resistance as compared to rifampicin resistance, i.e., any inactivating mutation within katG can result in isoniazid resistance, whereas only specific non-inactivating mutations in rpoB can result in rifampicin resistance. However, we observed that a single mutation in katG, which results in a substitution of serine to threonine at position 315, accounted for the majority of isoniazid-resistance arisals and that, overall, there were ~20% more independent arisals of resistance to rifampicin than there were to isoniazid, indicating that the relative rates of resistance in vivo may differ from those calculated in vitro.
Another possible explanation for the ordering is that isoniazidresistant strains, including those carrying the prevalent katG mutation encoding p.Ser315Thr, are more likely to develop resistance to other drugs. Although previous in vitro studies have shown a difference in the types of rifampicin-resistance-conferring mutations that arise on isoniazid-resistant backgrounds 39 , there is no evidence that isoniazid-resistant strains are transformed into 'hypermutators' (ref. 40 ). Furthermore, the sequence surrounding the Ser315 codon in katG does not seem to be susceptible to mutation nor does it seem to be a mutational hotspot in vitro 37 . However, as we and others have shown, this specific mutation is common among isoniazid-resistant clinical isolates, indicating that it is well tolerated in vivo. This is probably due to the fact that this mutation preserves mycobacterial catalase activity while still preventing activation of isoniazid 41 . This preserved fitness may affect the evolutionary adaptive landscape 42, 43 through which M. tuberculosis may acquire future resistance. Such a fitness landscape, which takes into account the relative fitness of different combinations of resistance-conferring and compensatory mutations, may produce a restricted set of evolutionary paths leading to MDR-TB.
A third possibility is that there is differential drug availability within the body, either due to pharmacokinetic effects 44, 45 or to differential rates of clinical penetration of the drugs into lesions 46 , that may influence the order of emergence of mutations. Current treatment regimens that result in suboptimal dosing of rifampicin [47] [48] [49] may result in effective mono-exposure to isoniazid, increasing the likelihood of developing isoniazid resistance first. Isoniazid preventative therapy (IPT) 50 , the treatment of suspected cases of latent TB with only isoniazid, could provide an opportunity for isoniazid resistance to develop before exposure to other drugs. However, IPT is not commonly used in most of the countries for which we have assembled data and, therefore, is unlikely to have a major role in the early arisal of isoniazid resistance in our data set.
Early identification and appropriate treatment of individuals with isoniazid-monoresistant strains, including treatment with nonisoniazid-based regimens 51 , may prevent the selection and eventual transmission of strains with resistance to additional drugs. The worldwide case rate of isoniazid monoresistance is estimated to be as high as 2-15% (refs. [52] [53] [54] [55] [56] , or 200,000-1,400,000 cases per year. Several studies have shown that patients harboring isoniazid-monoresistant strains have worse clinical outcomes than those harboring susceptible strains [57] [58] [59] , and enhanced treatment regimens for patients with such strains resulted in lower rates of treatment failure and acquired drug resistance 59 . A recent large meta-analysis revealed substantially worse treatment outcomes-including higher rates of MDR acquisitionwhen patients with isoniazid-resistant strains were treated with treatment regimens recommended by the World Health Organization that contained only first-line TB drugs 9 . One large retrospective cohort study also points to early detection of isoniazid monoresistance for improved outcomes 52 . In particular, the katG mutation encoding p.Ser315Thr has been associated with unfavorable treatment outcome and increased relapse in one population 60 . These and other results challenge the predictions of an earlier mathematical modeling study, which prognosticated that incorporation of isoniazid resistance onto a molecular test in India would provide only a negligible benefit to the control of MDR-TB 61 .
Our large data set confirms that Xpert MTB/RIF, currently the most widely used rapid molecular diagnostic for the diagnosis of M. tuberculosis and MDR-TB, performs excellently as a surrogate marker for multidrug resistance, irrespective of strain lineage and/or regional source. However, as it detects only rifampicinresistance-conferring mutations, Xpert MTB/RIF does not identify drug resistance at the earliest available opportunity. Thus, diagnostic algorithms that rely upon application of Xpert MTB/RIF alone will allow rifampicin-susceptible but otherwise drug-resistant strains to propagate unchecked. In fact, our evolutionary analysis indicates that, by the time a Xpert MTB/RIF-identifiable rifampicinresistance-conferring mutation is acquired, oftentimes multiple additional resistance-conferring mutations are already present. Additional commercially available diagnostics, such as the Hain MTBDRplus and Hain MTBDRsl ver. 2.0 line-probe assays, are available and detect a broader set of drug-resistance-conferring mutations. Despite logistical considerations that make practical application of this technology more difficult-such as moderate turnaround times and the need for specialized laboratory facilities-line-probe assays are able to detect isoniazid resistance (Hain MTBDRplus) with excellent specificity 62 . However, current diagnostic algorithms in certain TB-endemic countries 63 call for the application of these tests only after rifampicin resistance has been identified by Xpert MTB/RIF. Therefore, more comprehensive diagnostic tests are not being appropriately used to their full potential to identify rifampicin-susceptible but otherwise drug-resistant strains.
Through an evolutionary analysis of a diverse, global data set encompassing the genomes of 5,310 strains of M. tuberculosis, we observed that recent de novo emergence of MDR-TB in the past 10 years is a substantial contributor to global MDR today. Thus, to stem the development of additional MDR strains, one should seek to identify drug-resistant strains in the pre-MDR stage, during which there are additional therapeutic options and improved treatment outcomes. The identification of harbinger mutations, such as the katG mutation encoding p.Ser315Thr, may serve as an early warning signal that multidrug resistance may soon develop. Focusing on common, early-occurring mutations could improve the design of diagnostic tests that are aimed at targeting the earliest-occurring signatures of drug-resistant bacteria. Future prospective research will be needed to determine whether these harbinger mutations increase the risk of MDR M. tuberculosis emergence in a given population. If substantiated, then surveillance efforts for harbinger mutations may assist organizations to better allocate intensified TB control resources to at-risk areas and to target drug resistance in the pre-MDR stage. 
ONLINE METHODS
Whole-genome sequencing and data sets. References detailing the sequencing methods for the published data sets can be found in Supplementary Table 1 . Sequencing data for the TB Antibiotic Resistance Catalog (TB-ARC) projects ( Supplementary Table 1 ) were generated at the Broad Institute, as in Cohen et al. 6 . Additional information about samples for each of these unpublished projects can be found at the Broad Institute website (https://olive.broadinstitute. org/projects/tb_arc). The goal of the TB-ARC project was to create a catalog of mutations for antibiotic resistance in M. tuberculosis to inform diagnostics. As such, strains from each of the countries represented both drug-sensitive and drug-resistant isolates that would enable curation of such a catalog. For the data set from India, 223 drug-resistant and drug-sensitive strains, representative of lineages found in India (particularly lineages 1 and 3) were selected from studies in Tiruvallur and Madurai in Southern India and sequenced. For the MRC data set, 189 primarily drug-resistant strains from South Africa and Swaziland were selected for sequencing. For the CDRC data set, 179 genomes from South Korea and Uganda, with a wide variety of drugresistance patterns, as well as extensive characterization of drug-susceptibility profiles, were sequenced. For the data set from Sweden, 150 genomes were collected, primarily from Sweden's immigrant population. This set included a complete collection of all 141 MDR and XDR strains identified nationwide in Sweden in the period from 2003 to 2013. For the data set from Moldova, 95 genomes were selected from the countrywide specimen and data repositories. For the data set from Romania, 34 genomes were sequenced, with the goal of describing drug-resistant strains that were circulating in Romania and their diversity. For the data set from Iran, 33 primarily highly drug-resistant samples, including totally drug-resistant (TDR) samples, were sequenced.
The study protocol for these TB-ARC projects was approved by the Massachusetts Institute of Technology Committee on the Use of Humans as Experimental Subjects. Informed consent was obtained from all subjects, or else an appropriate waiver of consent was obtained.
For all of these TB-ARC projects, genomic DNA was extracted using published methods 65 . Library preparation and whole-genome sequencing (WGS) were performed as previously described on the Illumina HiSeq 2000 at the Broad Institute 66 . Sequencing data were submitted to the Sequence Read Archive (SRA) at NCBI under the umbrella BioProject identifiers listed in Supplementary Table 1. Alignments. Raw read data for 8,136 strains were downloaded from the SRA (see SRA accession codes in Supplementary Table 1 ). Reads were mapped onto the genomic sequence of the M. tuberculosis reference strain H37Rv (GenBank accession number CP003248.2) using BWA version 0.7.10 (ref. 67) . Variants were identified using Pilon version 1.11 as described 66 . The global M. tuberculosis lineage designations used in our analysis, as well as each strain's spoligotype, were predicted using digital spoligotyping, as described in Cohen et al. 6 .
We eliminated 824 strains that did not pass our quality control filters: average sequencing depth of coverage >20×; fraction of long insertions <0.2; ambiguity rate <0.5 (to remove samples that were suspected to represent mixes of different genotypes); number of low-coverage bases <250,000; and having a single match to one lineage in our lineage-prediction algorithm. We also eliminated strains for which Pilon analysis failed three times. Of the remaining 7,312 samples, we removed 1,970 strains with no 'country' metadata or description in a publication, 19 strains with substantial non-tuberculous mycobacterial contamination, as well as 13 additional duplicate patient samples. Use of these filters resulted in a final set of 5,310 strains for analysis.
The Emu software 68 was run to canonicalize variants. We conducted phylogenetic analyses for the entire set of 5,310 strains, as well as for a subset corresponding to each lineage and each United Nations geographical subregion with >30 strains (Supplementary Table 3) . For each set, all sites with unambiguous single-nucleotide polymorphisms (SNPs) in at least one strain were combined into a concatenated alignment. Ambiguous positions were treated as missing data. The concatenated alignment was then were used to generate a midpointrooted phylogenetic tree using FastTree 69 version 2.1.8.
Drug-resistance mutations.
A curated list of genomic polymorphisms that confer drug resistance was defined for eight drugs: rifampicin, ethambutol, isoniazid, ethionamide, ofloxacin, pyrazinamide, streptomycin and kanamycin. This was based on a literature review and consideration of current molecular drug-resistance diagnostics. All mutations incorporated in current molecular diagnostics in standard practice were included. This included the Xpert MTB/RIF 5 (http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/ critical-infectious-diseases/xpert-mtb-rif), the Hain Genotype MTBDRplus (http://www.hain-lifescience.de/en/products/microbiology/mycobacteria/ tuberculosis/genotype-mtbdrplus.html), the Hain Genotype MTBDRsl Line Probe Assay (http://www.hain-lifescience.de/en/products/microbiology/ mycobacteria/tuberculosis/genotype-mtbdrsl.html), as well as the Hain MTBDRsl Line Probe Assay v. 2.0 (http://www.hain-lifescience.de/en/products/ microbiology/mycobacteria/tuberculosis/genotype-mtbdrsl.html). Additional resistance-conferring mutations were selected for inclusion based on laboratory evidence and recent compelling genomic evidence that these mutations encode for resistance ( Supplementary Tables 4 and 5) . Because of greater uncertainty in calling longer variants in our data, we excluded insertions and deletions that were longer than 10 bp. Using this curated list, we identified 392 drugresistance-conferring mutations among the 231,898 total variants observed in our full data set across 5,310 strains.
Recent reports suggest that currently tabulated mutation sets account for the majority of phenotypic resistance 27, 70, 71 . Based on tabulated mutation sets, pyrazinamide phenotypic resistance was predicted with lower sensitivity, based on genotype, than other drugs in one recent analysis 70 . However, including all loss-of-function mutations in pncA in the mutation set, as we have done in this study, would likely greatly improve sensitivity in predicting phenotypic pyrazinamide resistance based on genotype.
Evolution of drug-resistance-conferring mutations. We used PAUP 72 version 4.0b10 to reconstruct gains and losses of drug-resistance-conferring mutations across the phylogenetic tree. We performed this analysis both for the full phylogeny of all 5,310 strains, as well as for individual phylogenies for each of the 11 geographic subregions and five lineages with >30 strains. PAUP was run using a cost matrix that assigned a 20× greater cost for a loss event relative to that of a gain event.
When examining the relative ordering of resistance-conferring mutations at two different nodes, we removed portions of the tree with potentially ambiguous topology. We removed node pairs from our analysis when the ancestral node had a bootstrap value <90%, as well as node pairs for which the longest of the individual branch lengths separating them was >10 −4 . 25% of the branches in our phylogeny had branch lengths >10 −4 . Our combined branch length and bootstrap filtering removed a total of 48% of the node pairs. Assigning dates to phylogeny nodes. BEAST 29 version 1.8.2 was used to estimate dates of acquisition of drug-resistance-conferring mutations in the phylogenies of strains belonging to lineages 1-4. Lineages 1 and 3 contained a small enough number of strains to run BEAST (494 and 431 strains, respectively). However, because the numbers of strains in lineages 2 and 4 were greater than those allowed by the current capabilities of the BEAST algorithm, we subdivided these lineages into subsets of 400-700 strains and ran BEAST separately on each of these subsets. First, we removed very closely related strains from lineages 2 and 4. To do this, we clustered strains using simple agglomerative hierarchical clustering. For each cluster that contained multiple sequences with <10 SNP differences in the core region aligning to H37RV, we kept only one strain. This reduced the number of unique strains in lineage 2 to 978, and the number of unique strains in lineage 4 to 1,556. We then manually examined the phylogenies to split the remaining lineage 2 strains into two clades (lineage 2a with 462 strains, and lineage 2b with 516 strains) and the remaining lineage 4 strains into three clades (lineage 4a with 423 strains, lineage 4b with 413 strains and lineage 4c with 720 strains). We constructed a phylogenetic tree for each of these seven subsets using FastTree 69 version 2.1.8 (one tree from lineage 1, two trees from lineage 2, one tree from lineage 3 and three trees from lineage 4). We then ran BEAST to estimate dates of acquisition of drug resistance mutations in these seven clades representing lineages 1-4.
Because of the large size of our data set and the small spread in sample isolation dates, we used simplified parameters and a fixed evolutionary rate. We ran BEAST twice, using two fixed values for the evolutionary rate (representing an upper and lower bound of possible evolutionary rates). Because of the wide range of evolutionary rates previously observed in M. tuberculosis, including varying rates for different strains 6, 12, 20, 38, [73] [74] [75] , we used a lower bound of 0.3 mutations per genome per year (ref. 73 ) and an upper bound of 0.6 mutations per genome per year (ref. 6) to cover the entire range of published rates across all lineages. Isolation dates for each sample were used as input to BEAST. If our metadata included only a range of isolation dates, then we selected the midpoint of this date range. We enforced the topology of our input tree that was generated using FastTree 69 . We used the following parameters when running BEAST: GTR, empirical base frequencies and no site heterogeneity model. BEAST was run for a minimum of 10 million iterations, sampling every 1,000 iterations. The program Tracer was used to examine mixing and effective sample size to assess chain length and model convergence. If the effective sample size (ESS) with 10 million iterations for all variables was not >100, then BEAST was run for additional iterations, until ESS values were all >100. The first 1 million iterations were excluded as 'burn-in' . Estimated dates are given with 95% highest-posterior-density (HPD) intervals.
We also used the BEAST data to calculate a date for the arisal of each MDR node. To calculate the number of strains descending from each MDR node, we included the closely related strains that were removed after performing the hierarchical clustering.
